FXR agonist 17 是一种口服有效的甾体类 FXR 激动剂,其 EC50 值分别为 42.2 nM(TR-FRET)和 176.4 nM(荧光素酶报告基因实验),可激活 TGR5(EC₅₀ = 2.6 μM)但不激活 hMRGPRX4,具有抗炎、保肝和抗纤维化作用,可改善代谢功能障碍相关脂肪性肝炎(NAFLD)活动度评分并降低肝纤维化严重程度,可用于 NAFLD、胆汁淤积性肝病和肝纤维化的研究。
产品编号: MS-R01432 CAS No.: 3107769-23-0 分子式: C29H46N2O3S 分子量: 502.75
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

FXR agonist 17 是一种口服有效的甾体类 FXR 激动剂,其 EC50 值分别为 42.2 nM(TR-FRET)和 176.4 nM(荧光素酶报告基因实验),可激活 TGR5(EC₅₀ = 2.6 μM)但不激活 hMRGPRX4,具有抗炎、保肝和抗纤维化作用,可改善代谢功能障碍相关脂肪性肝炎(NAFLD)活动度评分并降低肝纤维化严重程度,可用于 NAFLD、胆汁淤积性肝病和肝纤维化的研究。

生物实验数据

生物活性 FXR agonist 17 is an orally active steroidal FXR agonist with EC50 values of 42.2 nM (TR-FRET) and 176.4 nM (luciferase reporter assay), which activates TGR5 (EC₅₀ = 2.6 μM) but not hMRGPRX4, exhibits anti-inflammatory, hepatoprotective, and anti-fibrotic effects, improves the metabolic dysfunction-associated steatohepatitis (NAFLD) activity score and reduces liver fibrosis severity, and can be used for research on NAFLD, cholestatic liver disease, and liver fibrosis.
体外研究
(In Vitro)

FXR agonist 17 (Compound 10) (0.5-100 μM; 25 h) 在浓度≤ 40 μM 时对 RAW264.7 小鼠巨噬细胞无细胞毒性作用,但在浓度≥ 60 μM 时会降低细胞活力。
FXR agonist 17 (5-20 μM; 25 h) 可通过激活 FXR 呈剂量依赖性地减轻 RAW264.7 小鼠巨噬细胞中 LPS (MS-X54539) 诱导的炎症反应,其显著作用包括降低亚硝酸盐、TNF-α 和 ROS 水平,以及调控胆汁酸代谢和炎症相关基因的表达。
FXR agonist 17 (0-500 μM; 25 h) 在 HEK-293、HepG2 和 HEK-293 T 细胞中的 IC50 值分别为 62.2 μM、57 μM 和 46.3 μM。

Cell Viability Assay

Cell Line: RAW264.7 mouse macrophages
Concentration: 0.5, 1, 2, 5, 10, 20, 40, 60, 80, 100 μM
Incubation Time: 1 h pretreatment; 24 h LPS stimulation
Result: Showed no significant decrease in cell viability at concentrations ≤ 40 μM; showed significant cytotoxicity at 60, 80, and 100 μM.
体内研究
(In Vivo)

FXR agonist 17 (Compound 10) (20 mg/kg;口服;每日一次;连续 5 天) 可显著减轻经 ANIT 处理的雄性 C57BL/6 小鼠的胆汁淤积性肝损伤。
FXR agonist 17 (20 mg/kg;口服;每日一次;28 天) 可显著减轻 CCl4 处理的雄性 C57BL/6 小鼠的肝纤维化。
FXR agonist 17 (20 mg/kg;口服;每日一次;连续 28 天,于 12 周诱导期的第 8-12 周给药) 可显著改善雄性 C57BL/6 小鼠的肝脏病理状况。

Animal Model: C57BL/6 (male, 6-8 weeks old, SPF-grade, ANIT-induced)
Dosage: 20 mg/kg
Administration: p.o.; daily; 5 days
Result: Significantly reduced serum levels of ALP, TBA, and TBIL relative to the ANIT-induced group.
Reduced liver injury as evidenced by decreased cellular necrosis, inflammatory infiltration, and hemorrhage on H&E staining.
Lowered average H&E liver injury score to 4.0, compared to 6.2 in the ANIT-induced group.
Animal Model: C57BL/6 (male, 6-8 weeks old, SPF-grade, CCl4-induced)
Dosage: 20 mg/kg
Administration: p.o.; daily; 28 days
Result: Significantly reduced serum levels of TBA and TBIL relative to the CCl4-induced group.
Reduced hepatic collagen accumulation, with Sirius red-positive staining area decreasing to 1.48% from 1.98% in the CCl4-induced group.
Animal Model: C57BL/6 (male, 6-8 weeks old, SPF-grade, high-sugar high-fat diet + CCl4-induced)
Dosage: 20 mg/kg
Administration: p.o.; daily; 28 days (administered during weeks 8-12 of 12-week induction period)
Result: Significantly reduced serum levels of TC, HDL, and LDL relative to the MASH group.
Reduced hepatic triglyceride and total cholesterol levels relative to the MASH group.
Improved liver histopathology with reduced steatosis, lobular inflammation, and hepatocyte ballooning.
Lowered NAFLD activity score (NAS) to 4.0 from 5.9 in the MASH group.
Reduced hepatic collagen accumulation, with Sirius red-positive staining area decreasing to 1.75% from 2.55% in the MASH group.

化学信息

分子量 502.75
分子式 C29H46N2O3S
CAS No. 3107769-23-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础